Premium
Incidence of deferasirox‐associated renal tubular dysfunction in children and young adults with beta‐thalassaemia
Author(s) -
Dee Cathleen Michelle A.,
Cheuk Daniel Ka Leung,
Ha ShauYin,
Chiang Alan KwokShing,
Chan Godfrey ChiFung
Publication year - 2014
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.13002
Subject(s) - deferasirox , medicine , incidence (geometry) , beta thalassemia , pediatrics , beta (programming language) , thalassemia , physics , optics , computer science , programming language
mits, R., Mohren, M., Lengfelder, E., Reiser, M., Nickenig, C., Clemens, M., Peter, N., Bokemeyer, C., Eimermacher, H., Ho, A., Hoffmann, M., Mertelsmann, R., Trumper, L., Balleisen, L., Liersch, R., Metzner, B., Hartmann, F., Glass, B., Poeschel, V., Schmitz, N., Ruebe, C., Feller, A.C. & Loeffler, M. (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncology, 9, 105–116. Ziepert, M., Hasenclever, D., Kuhnt, E., Glass, B., Schmitz, N., Pfreundschuh, M. & Loeffler, M. (2010) Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. Journal of Clinical Oncology, 28, 2373–2380.